Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) J T Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

(2014) William Stohl   EXPERT OPINION ON THERAPEUTIC TARGETS

Systemic lupus erythematosus

(2014) Larissa Lisnevskaia et al.   LANCET

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

(2014) Maria Greenwald et al.   ARTHRITIS RESEARCH & THERAPY

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

(2013) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

(2013) Daniel J Wallace et al.   ANNALS OF THE RHEUMATIC DISEASES

Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment

(2013) Grainne Murphy et al.   LANCET

Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus

(2009) Michael P. Cancro et al.   JOURNAL OF CLINICAL INVESTIGATION

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM